Jomaa Pharma GmbH is developing a novel treatment for acute uncomplicated Plasmodium falciparum malaria which is based on a new and unique combination of two active pharmaceutical ingredients simultaneously affecting distinct targets in the parasite.
Recently, Jomaa proved that the drug combination comprising fosmidomycin and piperaquine was safe and efficacious in 50 patients providing for a 100 % cure rate at all defined time points post-treatment in a Phase II study in Gabon. No drug related side effects were observed. This clinical trial was followed by a Phase II study of fosmidomycin and piperaquine in children below the age of five years to establish efficacy in the most endangered patient group that is currently being evaluated - young children.
Jomaa Pharma GmbH is supported by Medicines for Malaria Venture (MMV) – a not for profit organisation funded by the Bill And Melinda Gates Foundation, European and Developing Countries Clinical Trials Programme (EDCTP) and World Health Organisation (WHO).